Sponsored information from

Primary care Action Interactive Cases

Return to homepage 

Anthony, 52

Anthony is a 52-year-old male who works as a taxi driver.

He is visiting you for his regularly scheduled type 2 diabetes (T2D) check-up.

Patient history and current medications

  • T2D diagnosis 15 years ago
  • Metformin (15 years), SGLT-2i (4 years), GLP-1 RA (2 years): all at optimum/ maximally tolerated dose
  • Non-smoker, moderate alcohol intake
  • Hypertension (CCB, 8 years)
  • Dyslipidaemia (statin, 8 years; ezetimibe, 2 years)
  • HbA1c target: <7.0% (53 mmol/mol)

Current clinical measurements

  • BMI 28 kg/m2 (12 months prior: BMI 29 kg/m2)
  • HbA1c 8.1% (65 mmol/mol)
  • BP 115/80 mmHg
  • LDL cholesterol 1.7 mmol/L (66 mg/dL)
  • ALT 21 U/L and AST 18 U/L
  • Additional information:
  • eGFR 81 mL/min/1.73 m2

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BP: blood pressure; CCB: calcium channel blocker; eGFR: estimated glomerular filtration rate; FIB-4: Fibrosis-4 index; GLP-1 RA: glucagon-like peptide-1 receptor agonist; LDL: low-density lipoprotein; SGLT-2i: sodium-glucose cotransporter-2 inhibitor

Hide medical notes 
Clinical data 

This is a fictional case study. The model is not a real patient and the situation shown does not reflect the model's experience.

References
  1. Vieira Barbosa J, Milligan S et al. Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol Commun 2022;6(4):765-779
  2. Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 2019;70(6):1885-1888
  3. Sterling R K, Lissen E et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-1325
  4. Davies M J, Aroda V R et al. Management of hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753-2786
  5. Diabetes UK. Chapter 5: psychological barriers to insulin use. Available at: diabetes.org.uk. Accessed March 2023
  6. Polonsky W H, Arsenault J et al. Initiating insulin: how to help people with type 2 diabetes start and continue insulin successfully. Int J Clin Pract 2017;71(8)
  7. Diabetes UK. Diabetes and your driving licence. Available at: diabetes.org.uk. Accessed March 2023
  8. Fadini G P, Buzzetti R et al. Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY). Acta Diabetol 2022;59(10):1317-1330
  9. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2016;40(1):155-157
  10. Dalal M R, Kazemi M et al. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: implications for treatment discontinuation and healthcare costs and utilization. Adv Ther 2017;34(9):2083-2092
  11. Owens D R, Traylor L et al. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract 2017;124:57-65
  12. Mehta R, Goldenberg R et al. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med 2021;53(1):998-1009
  13. Bradley M C, Chillarige Y et al. Severe hypoglycemia risk with long-acting insulin analogs vs neutral protamine Hagedorn insulin. JAMA Intern Med 2021;181(5):598-607
  14. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81(2):184-189
  15. Silbert R, Salcido-Montenegro A et al. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep 2018;18(8):53
  16. Institute for Quality and Efficiency in Health Care (IQWiG); Hyperglycemia and hypoglycemia in type 2 diabetes, 2006 (last updated October 2020). Available from: ncbi.nlm.nih.gov. Accessed January 2023
  17. UpToDate. Patient education: type 2 diabetes and diet (beyond the basics). Available at: uptodate.com. Accessed March 2023
  18. Kuritzky L, Reid T S, Wysham C H. Practical guidance on effective basal insulin titration for primary care providers. Clin Diabetes 2019;37(4):368-376
  19. US Pharmacist. How to initiate, titrate, and intensify insulin treatment in type 2 diabetes. Available at: uspharmacist.com. Accessed March 2023
  20. Cleveland Clinic. Lipohypertrophy. Available at: my.clevelandclinic.org. Accessed March 2023
  21. National Institute for Health and Care Excellence (NICE). NICE Clinical Knowledge Summary. Diabetes - type 2: Scenario: Management - adults (last updated October 2022). Available at: cks.nice.org.uk. Accessed March 2023